Skip to content

Comparison of the effect of the combination of two ureteral muscle relaxants and single drugs in candidate patients with renal stones

Comparison of adjuvant tadalafil and tamsulosin with tamsulosin alone in patients undergoing extracorporeal shockwave lithotripsy of renal stones

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240515061806N1
Enrollment
160
Registered
2024-08-07
Start date
2024-08-22
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal stone. Calculus of kidney

Interventions

Intervention 1: Intervention group1: receiving 5 mg of tadalafil and 0.4 mg of tamsulosin daily for two weeks. Intervention 2: 0.4 mg tamsulosin placebo tadalafil nightly.

Sponsors

Kerman University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients older than 18 years Having stones with a size between 5 and 20 mm in the kidney and proximal ureter

Exclusion criteria

Exclusion criteria: Having coagulation disorders pregnancy Creatinine clearance below 50 ml/min Liver dysfunction Urgent surgery is needed to remove stone blockage Presence of positive urine culture Patients with simultaneous unilateral or bilateral ureteral stones The distance between the stone and the skin is more than 12 cm History of previous unsuccessful extracorporeal lithotripsy Use of nitroglycerin and netirocanthine Lack of consent to participate in the study Systolic blood pressure below 90 mm Hg at the time of treatment initiation History of cataract History of hypersensitivity after taking tamsulosin or tadalafil History of back ache History of Severe digestive disorders after treatment History of priapism

Design outcomes

Primary

MeasureTime frame
Stone-free status. Timepoint: two weeks later. Method of measurement: CT Scan.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammadamin Hesamarefi

Kerman University of Medical Sciences

m.hesamarefi@gmail.com+98 34 3251 4232

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026